BSX stock forecast: what analysts expect
Wall Street analysts covering Boston Scientific Corporation currently rate the stock a Buy on average, with a mean 12-month price target of $62.69 — +21.9% versus the last price of $51.42. Targets reflect analyst opinion, not a guarantee.
BSX historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in BSX.
BSX annual returns by year
Congress trading in BSX
14 members of Congress have disclosed trading BSX — 23 purchases and 14 sales worth an estimated $297,738. Most recent disclosure: Jun 5, 2026.
See who in Congress traded BSX →Insider activity in BSX
BSX's own executives and directors have made 9 open-market purchases ($9.9M) and 0 sales ($0) in the last 90 days, per SEC Form 4 filings. Most recent: Aug 5, 2026.
| Aug 5, 2026 | Habiger David C | Director | Buy | $99,937 |
| Aug 4, 2026 | Habiger David C | Director | Buy | $6,802 |
| Aug 3, 2026 | Habiger David C | Director | Buy | $50,084 |
| Aug 3, 2026 | Mahoney Michael F | Chairman, President & CEO | Buy | $9.0M |
| Jul 31, 2026 | Ludwig Edward J | Director | Buy | $227,400 |
About Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
BSX Key Statistics
BSX in plain English
- P/E ratio (20.7) — how many dollars you pay for each $1 of BSX's yearly profit. That's a fairly normal range.
- ROE (15.34%) — how efficiently the company turns shareholders' money into profit. This is a middling level.
- Profit margin (17.50%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend — BSX doesn't pay a meaningful dividend; the return here comes from the share price, not cash payouts.
BSX stock: frequently asked questions
What is Boston Scientific Corporation's stock price today?
Boston Scientific Corporation (BSX) last traded at $51.42 on the NYSE. Over the past 52 weeks the stock has traded between $42.20 and $109.50.
Is BSX stock a buy or a sell?
Wall Street analysts' consensus rating on BSX is "Buy", with an average 12-month price target of $62.69 — about +21.9% versus the current price of $51.42. Analyst targets are opinions, not guarantees; always do your own research.
How much would $1,000 invested in BSX 10 years ago be worth today?
A $1,000 investment in Boston Scientific Corporation made 10 years ago would be worth about $2,159 today (dividends reinvested) — a total return of 116%, or 8.0% per year.
Does BSX pay a dividend?
No — Boston Scientific Corporation does not currently pay a meaningful dividend. Returns for shareholders come from changes in the share price.
What is BSX's P/E ratio?
BSX trades at a trailing price-to-earnings ratio of 20.7, and 15.0 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.
Do members of Congress trade BSX stock?
Yes — 14 members of Congress have disclosed trades in BSX under the STOCK Act, totaling 23 purchases and 14 sales worth an estimated $297,738.
What is Boston Scientific Corporation's ticker symbol?
Boston Scientific Corporation trades under the ticker symbol BSX on the NYSE.
Compare BSX with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.